Edge
StocktwitsEarnings

Official STOCKTWITS Representative
$GYRE Q2 '26 Earnings Results & Recap
• Reported GAAP EPS of -$0.12
• Reported revenue of $29.11M up 8.72% YoY
• Gyre Therapeutics, Inc. affirmed its full year 2026 revenue guidance of $100.5 million to $111.0 million, reflecting the company's outlook for its commercial-stage biopharmaceutical product portfolio and development initiatives.